Trials / Conditions / Waldenstrom's Macroglobulinemia Recurrent
Waldenstrom's Macroglobulinemia Recurrent
5 registered clinical trials studyying Waldenstrom's Macroglobulinemia Recurrent.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination Wit NCT05952037 | BeOne Medicines | Phase 2 |
| Terminated | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL NCT05360238 | Mustang Bio | Phase 1 / Phase 2 |
| Terminated | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product NCT05645744 | Mustang Bio | — |
| Terminated | Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia NCT03679624 | Weill Medical College of Cornell University | Phase 2 |
| Completed | A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia NCT04440059 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 |